Study to Screen for Psycho-sexual Health Disorders and Measure Neurochemical Correlation in Survivors of Gynaecological Cancers.

A Cross-Sectional Study to Screen for Psycho-sexual Health Disorders and Measure Neurochemical Correlates in Gynecology Cancer Survivors. - FSD

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

CTRI

Registry ID

CTRI/2022/02/040308

Enrollment

200

Registered

2022-02-15

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N879- Dysplasia of cervix uteri, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age more than 18 years. 2. Those who are seeking treatment at the department of gynaecology and obstetrics/radiation oncology for gynaecological cancer. 3. Gynaecological cancer survivors i.e. cervical, uterine, ovarian (including fallopian tube and peritoneal), vaginal. 4. Willing to participate in the study and provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who are suffering from any communication disability due to which they cannot be interviewed for the purpose of the study. 2. Diagnosed cases of psychiatric illness before diagnosis of malignancy.

Design outcomes

Primary

Measure	Time frame
Primary outcome measure: 1. Prevalence of depression in gynecological cancer survivors. 2. Prevalence of anxiety in gynecological cancer survivors. 3. Prevalence of psychological stress in gynecological cancer survivors. 4. Prevalence of sexual dysfunction in gynecological cancer survivors. 5. Prevalence of psychoactive substance use in gynecological cancer survivors. 6. Serum Substance P, BDNF, and Neuropeptide Y levels in gynecological cancer survivors and correlation of levels with other primary outcome measures.Timepoint: two to twenty-three months.	—

Measure

Time frame

Primary outcome measure: 1. Prevalence of depression in gynecological cancer survivors. 2. Prevalence of anxiety in gynecological cancer survivors. 3. Prevalence of psychological stress in gynecological cancer survivors. 4. Prevalence of sexual dysfunction in gynecological cancer survivors. 5. Prevalence of psychoactive substance use in gynecological cancer survivors. 6. Serum Substance P, BDNF, and Neuropeptide Y levels in gynecological cancer survivors and correlation of levels with other primary outcome measures.Timepoint: two to twenty-three months.

—

Secondary

Measure	Time frame
Secondary outcome measures: 1. Risk factors associated with sexual dysfunction in gynaecological cancer survivors. 2. Risk factors associated with depression, anxiety and psychoactive substance use in gynaecological cancer survivors. 3. Correlation of serum Substance P, BDNF and Neuropeptide Y levels in gynaecological cancer survivors with degree of depression, anxiety, stress, sexual dysfunction and psychoactive substance use in gynaecological cancer survivors.Timepoint: two to twenty-three months.	—

Measure

Time frame

Secondary outcome measures: 1. Risk factors associated with sexual dysfunction in gynaecological cancer survivors. 2. Risk factors associated with depression, anxiety and psychoactive substance use in gynaecological cancer survivors. 3. Correlation of serum Substance P, BDNF and Neuropeptide Y levels in gynaecological cancer survivors with degree of depression, anxiety, stress, sexual dysfunction and psychoactive substance use in gynaecological cancer survivors.Timepoint: two to twenty-three months.

—

Countries

India

Contacts

Public ContactDr Nilanchali Singh

AIIMS, New Delhi

nilanchalisingh@gmail.com9811343168

Outcome results